Mavacamten (DC11524) chemical structure
Chemical structureResearch use only
CAT. NO. DC11524Featured

Mavacamten (MYK-461)

Pack size & price

USD
Ready-made solution
Total$550
We match the best price and quality on market.
Product overview

Description & Application

Mavacamten (MYK-461) is a cardiac myosin inhibitor used to study sarcomere contractility and hypertrophic cardiomyopathy.

ParameterValue
Chemical NameMavacamten
CAS No.1642288-47-8
SynonymsMavacamten; QX45B99R3J; (S)-3-isopropyl-6-((1-phenylethyl)amino)pyrimidine-2,4(1H,3H)-dione; Mavacamten [INN]; Mavacamten [WHO-DD]; MYK461; GTPL11265; s8861; SAR439152; DB14921; SB19779; (S)-3-Isopropyl-6-((1-phenylethyl)amino) pyrimidine-2,4(1H,3H)-dione; (S)-3-Isopropyl-6-((1-phenylethyl)amino)pyrimidine-2, 4(1H,3H)-dione; (S)-3-Isopropyl-6
FormulaC15N3O2H19
M.Wt273.3303
SMILESO=C1N([H])C(=C([H])C(N1C([H])(C([H])([H])[H])C([H])([H])[H])=O)N([H])[C@@]([H])(C([H])([H])[H])C1C([H])=C([H])C([H])=C([H])C=1[H]
Purity98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Cardiac myosin · Literature evidence

Biological Activity

Mavacamten (MYK-461) is a cardiac myosin inhibitor used to study sarcomere contractility and hypertrophic cardiomyopathy. Reduced contractility by decreasing ATPase activity of cardiac myosin heavy chain.

In Vitro

EndpointModel / conditions / sourceReported result
Cardiac myosin mechanismMYK-461 sarcomere experiments. [1]Reduced contractility by decreasing ATPase activity of cardiac myosin heavy chain.

In Vivo

EndpointModel / conditions / sourceReported result
Genetic cardiomyopathy modelsMice carrying heterozygous human myosin-heavy-chain mutations. [1]Early chronic treatment suppressed ventricular hypertrophy, cardiomyocyte disarray and myocardial fibrosis.
Gene-expression responseTreated mouse heart tissue. [1]Hypertrophic and profibrotic transcriptional changes were attenuated.

Compound and Evidence Context

EndpointModel / conditions / sourceReported result
Timing and interpretationPrevention-oriented early-treatment experiments. [1]These findings do not demonstrate complete reversal of all established disease. Dose and exposure details require the corresponding full protocol.

Interpretation

Prevention during early treatment is not the same as reversal of established advanced disease.

Original studies

Original study and figures ↗

References

  1. Green EM, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science (New York, N.Y.) (2016).

Product documentation

View COAView MSDSView online datasheet

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

For additional quantities or product documentation, contact info@dcchemicals.com.

Solution calculatorBrowse small molecules

Related research products

Laropiprant chemical structureDC1009

Laropiprant

Laropiprant is a DP1 receptor antagonist for prostanoid signaling and platelet-function research. Its effects on platelet activation vary with agonist and concentration.

View activity & prices

Cart

Request quotation